Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2011 (2011), Article ID 891819, 7 pages
http://dx.doi.org/10.1155/2011/891819
Research Article

Aqueous and Ethanolic Valeriana officinalis Extracts Change the Binding of Ligands to Glutamate Receptors

Department of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, P.O. Box 365067, San Juan, 00936-5067 Puerto Rico, USA

Received 12 June 2009; Revised 6 July 2010; Accepted 27 October 2010

Copyright © 2011 Lisa M. Del Valle-Mojica et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. S. Miyasaka, A. N. Atallah, and B. G. O. Soares, “Valerian for anxiety disorders,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD004515, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. P. J. Houghton, “The scientific basis for the reputed activity of valerian,” Journal of Pharmacy and Pharmacology, vol. 51, no. 5, pp. 505–512, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Diaper and I. Hindmarch, “A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults,” Phytotherapy Research, vol. 18, no. 10, pp. 831–836, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Schulz, R. Hänsel, M. Blumenthal, and V. E. Tyler, Rational Phytotherapy: A Reference Guide for Physicians and Pharmacists, Springer, Berlin, Germany, 5th edition, 2004.
  5. M. S. Santos, F. Ferreira, A. P. Cunha, A. P. Carvalho, and T. Macedo, “An aqueous extract of valerian influences the transport of GABA in synaptosomes,” Planta Medica, vol. 60, no. 3, pp. 278–279, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. M. S. Santos, F. Ferreira, A. P. Cunha, A. P. Carvalho, C. F. Ribeiro, and T. Macedo, “Synaptosomal GABA release as influenced by valerian root extract—involvement of the GABA carrier,” Archives Internationales de Pharmacodynamie et de Therapie, vol. 327, no. 2, pp. 220–231, 1994. View at Google Scholar · View at Scopus
  7. C. Cavadas, I. Araujo, M. D. Cotrim et al., “In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABA(A) receptor in rat brain,” Arzneimittel-Forschung/Drug Research, vol. 45, no. 7, pp. 753–755, 1995. View at Google Scholar · View at Scopus
  8. J. G. Ortiz, J. Nieves-Natal, and P. Chavez, “Effects of Valeriana Officinalis extracts on [H]3flunitrazepam binding, synaptosomal [H]3GABA uptake, and hippocampal [H]3GABA release,” Neurochemical Research, vol. 24, no. 11, pp. 1373–1378, 1999. View at Google Scholar · View at Scopus
  9. C.-S. Yuan, S. Mehendale, Y. Xiao, H. H. Aung, J.-T. Xie, and M. K. Ang-Lee, “The gamma-aminobutyric acidergic effects of valerian and Valerenic acid on rat brainstem neuronal activity,” Anesthesia and Analgesia, vol. 98, no. 2, pp. 353–358, 2004. View at Google Scholar · View at Scopus
  10. W. Neuhaus, G. Trauner, D. Gruber et al., “Transport of a CABAA receptor modulator and its derivatives from Valeriana officinalis L s. I. across an in vitro cell culture model of the blood-brain barrier,” Planta Medica, vol. 74, no. 11, pp. 1338–1344, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. O. Malva, S. Santos, and T. Macedo, “Neuroprotective properties of Valeriana officinalis extracts,” Neurotoxicity Research, vol. 6, no. 2, pp. 131–140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding,” Analytical Biochemistry, vol. 72, no. 1-2, pp. 248–254, 1976. View at Google Scholar · View at Scopus
  13. S. Bent, A. Padula, D. Moore, M. Patterson, and W. Mehling, “Valerian for sleep: a systemic review and meta-analysis,” American Journal of Medicine, vol. 119, no. 12, pp. 1005–1012, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. P. D. Leathwood, F. Chauffard, E. Heck, and R. Munoz-Box, “Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man,” Pharmacology Biochemistry and Behavior, vol. 17, no. 1, pp. 65–71, 1982. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Stevinson and E. Ernst, “Valerian for insomnia: a systematic review of randomized clinical trials,” Sleep Medicine, vol. 1, no. 2, pp. 91–99, 2000. View at Google Scholar · View at Scopus
  16. R. Andreatini, V. A. Sartori, M. L. V. Seabra, and J. R. Leite, “Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study,” Phytotherapy Research, vol. 16, no. 7, pp. 650–654, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Leuschner, J. Müller, and M. Rudmann, “Characterisation of the central nervous depressant activity of a commercially available valerian root extract,” Arzneimittel-Forschung/Drug Research, vol. 43, no. 6, pp. 638–641, 1993. View at Google Scholar · View at Scopus
  18. O. Lindahl and L. Lindwall, “Double blind study of a Valerian preparation,” Pharmacology Biochemistry and Behavior, vol. 32, no. 4, pp. 1065–1066, 1989. View at Publisher · View at Google Scholar · View at Scopus
  19. P. D. Leathwood and F. Chauffard, “Aqueous extract of valerian reduces latency to fall asleep in man,” Planta Medica, no. 2, pp. 144–148, 1985. View at Google Scholar · View at Scopus
  20. M. Hattesohl, B. Feistel, H. Sievers, R. Lehnfeld, M. Hegger, and H. Winterhoff, “Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties,” Phytomedicine, vol. 15, no. 1-2, pp. 2–15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Benke, A. Barberis, S. Kopp et al., “GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts,” Neuropharmacology, vol. 56, no. 1, pp. 174–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Hendriks, R. Bos, H. J. Woerdenbag, and A. S. Koster, “Central nervous depressant activity of valerenic acid in the mouse,” Planta Medica, vol. 1, pp. 28–31, 1985. View at Google Scholar · View at Scopus
  23. C. Wasowski, M. Marder, H. Viola, J. H. Medina, and A. C. Paladini, “Isolation and identification of 6-methylapigenin, a competitive ligand for the brain GABAA receptors, from Valeriana wallichii,” Planta Medica, vol. 68, no. 10, pp. 934–936, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Schumacher, S. Scholle, J. Hölzl, N. Khudeir, S. Hess, and C. E. Müller, “Lignans isolated from Valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors,” Journal of Natural Products, vol. 65, no. 10, pp. 1479–1485, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Marder, H. Viola, C. Wasowski, S. Fernández, J. H. Medina, and A. C. Paladini, “6-Methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS,” Pharmacology Biochemistry and Behavior, vol. 75, no. 3, pp. 537–545, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Fernández, C. Wasowski, A. C. Paladini, and M. Marder, “Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis,” Pharmacology Biochemistry and Behavior, vol. 77, no. 2, pp. 399–404, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. R. E. Granger, E. L. Campbell, and G. A. R. Johnston, “(+)- and ()-borneol: efficacious positive modulators of GABA action at human recombinant α1β2γ2LGABAA receptors,” Biochemical Pharmacology, vol. 69, no. 7, pp. 1101–1111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Q. Gao and L. Björk, “Valerenic acid derivatives and valepotriates among individuals, varieties and species of Valeriana,” Fitoterapia, vol. 71, no. 1, pp. 19–24, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Navarrete, B. Avula, Y.-W. Choi, and I. A. Khan, “Chemical fingerprinting of valeriana species: simultaneous determination of valerenic acids, flavonoids, and phenylpropanoids using liquid chromatography with ultraviolet detection,” Journal of AOAC International, vol. 89, no. 1, pp. 8–15, 2006. View at Google Scholar · View at Scopus
  30. I. Oliva, M. E. González-Trujano, J. Arrieta, R. Enciso-Rodríguez, and A. Navarrete, “Neuropharmacological profile of hydroalcohol extract of Valeriana edulis ssp. procera roots in mice,” Phytotherapy Research, vol. 18, no. 4, pp. 290–296, 2004. View at Publisher · View at Google Scholar
  31. C. Circosta, R. De Pasquale, S. Samperi, A. Pino, and F. Occhiuto, “Biological and analytical characterization of two extracts from Valeriana officinalis,” Journal of Ethnopharmacology, vol. 112, no. 2, pp. 361–367, 2007. View at Publisher · View at Google Scholar
  32. F. Occhiuto, A. Pino, D. R. Palumbo et al., “Relaxing effects of Valeriana officinalis extracts on isolated human non-pregnant uterine muscle,” Journal of Pharmacy and Pharmacology, vol. 61, no. 2, pp. 251–256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J. G. Ortiz, N. Rassi, P. M. Maldonado, S. González-Cabrera, and I. Ramos, “Commercial Valerian interactions with [H3]flunitrazepam and [H3]MK-801 binding to rat synaptic membranes,” Phytotherapy Research, vol. 20, no. 9, pp. 794–798, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Chojnacka-Wójcik, A. Klodzinska, and A. Pilc, “Glutamate receptor ligands as anxiolytics,” Current Opinion in Investigational Drugs, vol. 2, no. 8, pp. 1112–1119, 2001. View at Google Scholar · View at Scopus
  35. A. Palucha and A. Pilc, “Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs,” Pharmacology and Therapeutics, vol. 115, no. 1, pp. 116–147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. C. J. Swanson, M. Bures, M. P. Johnson, A.-M. Linden, J. A. Monn, and D. D. Schoepp, “Metabotropic glutamate receptors as novel targets for anxiety and stress disorders,” Nature Reviews Drug Discovery, vol. 4, no. 2, pp. 131–144, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. D. D. Schoepp, R. A. Wright, L. R. Levine, B. Gaydos, and W. Z. Potter, “LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress,” Stress, vol. 6, no. 3, pp. 189–197, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. W. P. J. M. Spooren, A. Vassout, H. C. Neijt et al., “Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 3, pp. 1267–1275, 2000. View at Google Scholar · View at Scopus
  39. Valerian: product review, http://www.consumerlab.com.
  40. R. Bos, H. J. Woerdenbag, H. Hendriks et al., “Analytical aspects of phytotherapeutic valerian preparations,” Phytochemical Analysis, vol. 7, no. 3, pp. 143–151, 1996. View at Google Scholar · View at Scopus